Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joanne S. Eglovitch

Senior Editor

Washington DC
Joanne Serpick Eglovitch is a senior editor for Pink Sheet where she writes about manufacturing quality issues. Joanne has over 20 years of experience covering the regulated pharmaceutical and medical device industries, and helped launch the “International Pharmaceutical Regulatory Monitor” and the “International Medical Device Regulatory Monitor”. Previously Joanne covered the mortgage finance industry and the mortgage capital markets, and employment and training programs. Before her forays into newsletter journalism, Joanne worked as a general assignment reporter for a twice-weekly newspaper in southern Maryland and an editorial assistant for “Insight” Magazine, published by “The Washington Times.”
Set Alert for Articles By Joanne S. Eglovitch

Latest From Joanne S. Eglovitch

In Pandemic Response, Quality Experts Advise Drug Manufacturers Move Products To Local Sites

AstraZeneca emptied its warehouses in January. “We said, OK let us pack everything and get it out in the door,” said Tony Mire-Sluis, head of global quality. The firm is allowing only crucial personnel in plants, or those responsible for running a plant or moving products; all others are working from home.

Coronavirus COVID-19 OTC Drugs

Quality Experts Advise Industry To Move Products To Local Sites In Responding To COVID-19

Quality experts with AstraZeneca and Thermo Fisher describe how their companies are responding to the COVID-19 pandemic – but urge industry not to lose focus on monitoring unrelated drug products.

Manufacturing Quality

FDA Warning Letters Hit Small OTC, Large Pharma Firms With Same Citations In FY 2019

Inadequate process controls and faulty failure investigations were the top GMP violations found in warning letters sent in FY 2019 to companies large and small.

Manufacturing Quality

Cipla Plant Gets FDA Warning Letter

Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.

Manufacturing India

US FDA Suspends Domestic Inspections As Staff Work Remotely In Covid-19 Response

Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.

Coronavirus COVID-19 Regulation

API In Ducts And Filters Led To Cipla’s First Drug GMP Warning Letter

Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.

Manufacturing Quality
See All
UsernamePublicRestriction

Register